BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.

Pour L, Delimpasi S, Legiec W, Minarik J, Spicka I, Grosicki S, Rymko M, Najda J, Symeonidis A, Andersson B, Huledal G, Norin S, Dimopoulos MA

Open source

DOI
10.1016/j.clml.2026.04.022
Published
2026 Jul
Container
Clinical lymphoma, myeloma & leukemia
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clml.2026.04.022,
  title = {BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.},
  author = {Pour L and Delimpasi S and Legiec W and Minarik J and Spicka I and Grosicki S and Rymko M and Najda J and Symeonidis A and Andersson B and Huledal G and Norin S and Dimopoulos MA},
  year = {2026},
  journal = {Clinical lymphoma, myeloma \& leukemia},
  doi = {10.1016/j.clml.2026.04.022},
  url = {https://doi.org/10.1016/j.clml.2026.04.022}
}

RIS

TY  - JOUR
TI  - BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.
AU  - Pour L
AU  - Delimpasi S
AU  - Legiec W
AU  - Minarik J
AU  - Spicka I
AU  - Grosicki S
AU  - Rymko M
AU  - Najda J
AU  - Symeonidis A
AU  - Andersson B
AU  - Huledal G
AU  - Norin S
AU  - Dimopoulos MA
PY  - 2026
JO  - Clinical lymphoma, myeloma & leukemia
DO  - 10.1016/j.clml.2026.04.022
UR  - https://doi.org/10.1016/j.clml.2026.04.022
ER  - 

APA

L, P., S, D., W, L., J, M., I, S., S, G., M, R., J, N., A, S., B, A., G, H., S, N., & MA, D. (2026). BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.04.022

Source records